Which has preferable earnings and valuation, KOD or ABVX?

Abivax is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is KOD or ABVX more profitable?

Abivax's return on equity of -99.02% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Abivax N/A -99.02% -70.26%

Which has stronger earnings and valuation, QGEN or KOD?

Qiagen has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 3.67 $424.88M $1.91 19.50 Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is QGEN or KOD more profitable?

Qiagen has a net margin of 19.16% compared to Kodiak Sciences' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.16% 14.40% 8.40% Kodiak Sciences N/A -253.85% -81.48%

Is PRAX or KOD more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Kodiak Sciences N/A -253.85% -81.48%

Kodiak Sciences (KOD) Competitors

$37.05 +0.42 (+1.15%)

As of 04:00 PM Eastern

Compare

KOD vs. ABVX, QGEN, TGTX, IBRX, and PRAX

Should you buy Kodiak Sciences stock or one of its competitors? MarketBeat compares Kodiak Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kodiak Sciences include Abivax (ABVX), Qiagen (QGEN), TG Therapeutics (TGTX), ImmunityBio (IBRX), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Kodiak Sciences compare to Abivax?

Kodiak Sciences (NASDAQ:KOD) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

In the previous week, Abivax had 7 more articles in the media than Kodiak Sciences. MarketBeat recorded 7 mentions for Abivax and 0 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.55 beat Abivax's score of 0.28 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Kodiak Sciences	Positive
Abivax	Neutral

Kodiak Sciences has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Abivax has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Abivax is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Abivax's return on equity of -99.02% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Abivax	N/A	-99.02%	-70.26%

Kodiak Sciences currently has a consensus price target of $42.14, indicating a potential upside of 13.75%. Abivax has a consensus price target of $130.08, indicating a potential upside of 32.15%. Given Abivax's stronger consensus rating and higher probable upside, analysts plainly believe Abivax is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 45.9% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Kodiak Sciences beats Abivax on 7 of the 13 factors compared between the two stocks.

How does Kodiak Sciences compare to Qiagen?

Qiagen (NYSE:QGEN) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Qiagen has a net margin of 19.16% compared to Kodiak Sciences' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Kodiak Sciences	N/A	-253.85%	-81.48%

Qiagen has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Qiagen has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.67	$424.88M	$1.91	19.50
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Qiagen currently has a consensus price target of $44.71, indicating a potential upside of 20.02%. Kodiak Sciences has a consensus price target of $42.14, indicating a potential upside of 13.75%. Given Qiagen's higher possible upside, analysts clearly believe Qiagen is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.46
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

70.0% of Qiagen shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 45.9% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Qiagen had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 2 mentions for Qiagen and 0 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.55 beat Qiagen's score of 0.37 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Qiagen	Neutral
Kodiak Sciences	Positive

Summary

Qiagen beats Kodiak Sciences on 10 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

TG Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.40	$447.18M	$2.86	18.86
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

In the previous week, TG Therapeutics had 6 more articles in the media than Kodiak Sciences. MarketBeat recorded 6 mentions for TG Therapeutics and 0 mentions for Kodiak Sciences. TG Therapeutics' average media sentiment score of 0.59 beat Kodiak Sciences' score of 0.55 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TG Therapeutics	Positive
Kodiak Sciences	Positive

TG Therapeutics currently has a consensus target price of $58.60, indicating a potential upside of 8.64%. Kodiak Sciences has a consensus target price of $42.14, indicating a potential upside of 13.75%. Given Kodiak Sciences' higher probable upside, analysts clearly believe Kodiak Sciences is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

TG Therapeutics has a net margin of 65.95% compared to Kodiak Sciences' net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Kodiak Sciences	N/A	-253.85%	-81.48%

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

TG Therapeutics beats Kodiak Sciences on 11 of the 16 factors compared between the two stocks.

How does Kodiak Sciences compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Kodiak Sciences has lower revenue, but higher earnings than ImmunityBio. Kodiak Sciences is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	67.67	-$351.40M	-$0.85	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 45.9% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 93.99%. Kodiak Sciences has a consensus price target of $42.14, indicating a potential upside of 13.75%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

In the previous week, ImmunityBio had 1 more articles in the media than Kodiak Sciences. MarketBeat recorded 1 mentions for ImmunityBio and 0 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.55 beat ImmunityBio's score of 0.10 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmunityBio	Neutral
Kodiak Sciences	Positive

Kodiak Sciences has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Kodiak Sciences	N/A	-253.85%	-81.48%

Summary

ImmunityBio beats Kodiak Sciences on 9 of the 14 factors compared between the two stocks.

How does Kodiak Sciences compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Kodiak Sciences (NASDAQ:KOD) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Praxis Precision Medicines' return on equity of -43.02% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Kodiak Sciences	N/A	-253.85%	-81.48%

Praxis Precision Medicines presently has a consensus price target of $566.21, suggesting a potential upside of 85.42%. Kodiak Sciences has a consensus price target of $42.14, suggesting a potential upside of 13.75%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Praxis Precision Medicines has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Kodiak Sciences has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	995.76	-$303.27M	-$13.37	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

In the previous week, Praxis Precision Medicines had 8 more articles in the media than Kodiak Sciences. MarketBeat recorded 8 mentions for Praxis Precision Medicines and 0 mentions for Kodiak Sciences. Praxis Precision Medicines' average media sentiment score of 0.77 beat Kodiak Sciences' score of 0.55 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Overall Sentiment
Praxis Precision Medicines	Positive
Kodiak Sciences	Positive

Summary

Praxis Precision Medicines beats Kodiak Sciences on 10 of the 15 factors compared between the two stocks.

Get Kodiak Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KOD vs. The Competition

Export

Metric	Kodiak Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.29B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-8.88	19.75	24.92	23.97
Price / Sales	N/A	329.42	528.81	109.59
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	12.47	8.29	10.79	6.50
Net Income	-$229.97M	$23.85M	$3.56B	$336.88M
7 Day Performance	12.48%	5.21%	1.67%	-0.22%
1 Month Performance	2.26%	2.19%	0.43%	0.77%
1 Year Performance	920.66%	60.99%	32.84%	31.57%

Kodiak Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KOD Kodiak Sciences	1.6158 of 5 stars	$37.05 +1.1%	$42.14 +13.7%	+911.9%	$2.29B	N/A	N/A	90
ABVX Abivax	3.3554 of 5 stars	$98.26 +1.8%	$130.08 +32.4%	+1,602.8%	$7.70B	N/A	N/A	61	Options Volume Gap Up
QGEN Qiagen	4.5913 of 5 stars	$36.97 -0.3%	$44.98 +21.7%	-25.9%	$7.64B	$2.09B	19.31	5,654	Analyst Upgrade Gap Up
TGTX TG Therapeutics	2.9676 of 5 stars	$50.30 +1.6%	$52.50 +4.4%	+51.0%	$7.58B	$616.29M	17.59	290	Analyst Forecast
IBRX ImmunityBio	2.9147 of 5 stars	$7.13 +0.4%	$14.20 +99.2%	+151.6%	$7.44B	$113.29M	N/A	590	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KOD) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kodiak Sciences (KOD) Competitors

KOD vs. ABVX, QGEN, TGTX, IBRX, and PRAX

How does Kodiak Sciences compare to Abivax?

Summary

How does Kodiak Sciences compare to Qiagen?

Summary

How does Kodiak Sciences compare to TG Therapeutics?

Summary

How does Kodiak Sciences compare to ImmunityBio?

Summary

How does Kodiak Sciences compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kodiak Sciences (KOD) Competitors

KOD vs. ABVX, QGEN, TGTX, IBRX, and PRAX

How does Kodiak Sciences compare to Abivax?

Does the media favor KOD or ABVX?

Which has more risk & volatility, KOD or ABVX?

Which has preferable earnings and valuation, KOD or ABVX?

Is KOD or ABVX more profitable?

Do analysts recommend KOD or ABVX?

Do insiders and institutionals have more ownership in KOD or ABVX?

Summary

How does Kodiak Sciences compare to Qiagen?

Is QGEN or KOD more profitable?

Which has more volatility & risk, QGEN or KOD?

Which has stronger earnings and valuation, QGEN or KOD?

Do analysts rate QGEN or KOD?

Do institutionals and insiders believe in QGEN or KOD?

Does the media favor QGEN or KOD?

Summary

How does Kodiak Sciences compare to TG Therapeutics?

Which has more risk and volatility, TGTX or KOD?

Which has preferable valuation and earnings, TGTX or KOD?

Does the media prefer TGTX or KOD?

Do analysts rate TGTX or KOD?

Is TGTX or KOD more profitable?

Do insiders and institutionals have more ownership in TGTX or KOD?

Summary

How does Kodiak Sciences compare to ImmunityBio?

Which has better valuation and earnings, IBRX or KOD?

Do institutionals and insiders believe in IBRX or KOD?

Do analysts rate IBRX or KOD?

Which has more risk & volatility, IBRX or KOD?

Does the media prefer IBRX or KOD?

Is IBRX or KOD more profitable?

Summary

How does Kodiak Sciences compare to Praxis Precision Medicines?

Is PRAX or KOD more profitable?

Do analysts prefer PRAX or KOD?

Do insiders and institutionals hold more shares of PRAX or KOD?

Which has more risk & volatility, PRAX or KOD?

Which has better earnings and valuation, PRAX or KOD?

Does the media refer more to PRAX or KOD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KOD vs. The Competition

Kodiak Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools